Keytruda

What happened a year ago this week in biopharma? August 12-18, 2018
Regeneron
Novartis
wet-AMD
Eylea
ethics
Vertex Pharmaceuticals
Kalydeco
cystic fibrosis
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
SCLC
Flag link:
What happened a year ago this week in biopharma? August 12-18, 2018
What happened a year ago this week in biopharma? August 12-18, 2018
CP WIre
Regeneron
Novartis
wet-AMD
Eylea
ethics
Vertex Pharmaceuticals
Kalydeco
cystic fibrosis
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
SCLC
Flag link:
How Merck Could Ride 'The Keytruda Wave' To Dominate These Rivals
How Merck Could Ride 'The Keytruda Wave' To Dominate These Rivals
Investors Business Daily
Merck
Keytruda
cancer
Flag link:
MSD’s Keytruda plus chemo backed by NICE for lung cancer
MSD’s Keytruda plus chemo backed by NICE for lung cancer
Pharmaforum
Merck
Keytruda
NICE
non-small cell lung cancer
Flag link:
Leap zeroes in on subgroup for DKN-01, Keytruda combo
Leap zeroes in on subgroup for DKN-01, Keytruda combo
BioCentury
Leap Therapeutics
DKN-01
Keytruda
gastric cancer
Flag link:
These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024
These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024
Yahoo/Motley Fool
Merck
Keytruda
AbbVie
Humira
Pfizer
Bristol-Myers Squibb
Eliquis
JNJ
Imbruvica
Flag link:
Merck's Keytruda makes the cut as a second-line monotherapy for certain esophageal cancer patients
Merck's Keytruda makes the cut as a second-line monotherapy for certain esophageal cancer patients
Endpoints
Merck
Keytruda
esophageal cancer
Flag link:
Sales gap grows between rival Merck, Bristol cancer therapies
Sales gap grows between rival Merck, Bristol cancer therapies
Biopharma Dive
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
cancer
Flag link:
Merck Data Are Another Step for Immunotherapy in Breast Cancer
Merck Data Are Another Step for Immunotherapy in Breast Cancer
Xconomy
Merck
Keytruda
clinical trials
triple negative breast cancer
Flag link:
Bristol, With Another Lung Cancer Flop, Loses More Ground to Merck
Bristol, With Another Lung Cancer Flop, Loses More Ground to Merck
Xconomy
Bristol-Myers Squibb
Merck
Keytruda
Opdivo
non-squamous
non-squamous non-small cell lung cancer
Flag link:
Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY
Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY
Yahoo/Zacks.com
GSK
HIV
FDA
Merck
Keytruda
Sanofi
isatuximab
Roche
JNJ
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Merck
Keytruda
Melinta Therapeutics
Amag Pharmaceuticals
Palatin
Acer Therapeutics
Sanofi
Regeneron
Alexion
Pfizer
Roche
Navidea Biopharmaceuticals
Ascendis Pharma
Scholar Rock
Adaptive Biotechnologies
BridgeBio
IPOs
G Medical Innovations
Karuna
Morphic Therapeutics
Flag link:
Strength of Oncology Pipeline Touted at Merck’s First Investor Day in Five Years
Strength of Oncology Pipeline Touted at Merck’s First Investor Day in Five Years
BioSpace
Merck
Keytruda
investors
Flag link:
Investor day prep at Merck includes a new strategy to pick up the pace on M&A
Investor day prep at Merck includes a new strategy to pick up the pace on M&A
Endpoints
Merck
investors
Keytruda
cancer
M&A
Flag link:
Meet the Top Ten Drugs of 2024 (Maybe)
Meet the Top Ten Drugs of 2024 (Maybe)
Drug Channels
AbbVie
Humira
Merck
Keytruda
Eliquis
Bristol-Myers Squibb
Imbruvica
Opdivo
Revlimid
Celgene
Flag link:
Stepping on Roche's toes, Merck cuts into SCLC niche with second-line Keytruda OK
Stepping on Roche's toes, Merck cuts into SCLC niche with second-line Keytruda OK
Endpoints
Roche
Merck
SCLC
Keytruda
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Yahoo/Benzinga
ADA
Merck
Keytruda
NGM Biopharmaceuticals
NGM313/MK-3655
Corbus Pharmaceuticals
Nektar
Galapagos
Kezar Life Sciences
Kura Oncology
Bluebird Bio
BeiGene
Global Blood Therapeutics
Blueprint Medicines
Regeneron
Arqule
Sunesis
Sutro BioPharma
Incyte
Geron
Forty Seven
Flag link:
3 takeaways from cancer's biggest conference
3 takeaways from cancer's biggest conference
Biopharma Dive
Amgen
KRAS
accelerated approvals
Turning Point Therapeutics
Keytruda
Opdivo
ASCO 2019
Flag link:
ASCO Soundbites, vol. 3: Real-time approvals, Pfizer's second rodeo and 'the busiest ASCO ever'
ASCO Soundbites, vol. 3: Real-time approvals, Pfizer's second rodeo and 'the busiest ASCO ever'
Fierce Pharma
ASCO 2019
Merck
Keytruda
FDA
Pfizer
AstraZeneca
Regeneron
Libtayo
Venclexta
Gazyva
Flag link:
3 Drug Stocks That Could Win From Key FDA Approvals in June
3 Drug Stocks That Could Win From Key FDA Approvals in June
Motley Fool
Merck
Amag Pharmaceuticals
Alexion Pharma
FDA
Keytruda
Vyleesi
Soliris
Flag link:

Pages